Citations

Showing 10 of 108094 citations.

Abstract 1226: A genome wide pharmacological perturbation platform
Ung, Choong Yong , Correia, Cristina , Zhang, Cheng , Kaufmann, Scott H. , Li, Hu

Mayo Clinic

Cancer Research | June 15, 2022 | Volume: 82 | Issue: 12_Supplement | Pages: 1226-1226

10.1158/1538-7445.am2022-1226 Get It

Abstract Background: Large scale genetic perturbations screens have been instrumental for many key discoveries. In the last decade sequence specific genetic perturbations created RNAi and CRISPR (PMID: 25446316). Recently, specific genome targeting approaches using single guide RNAs (sgRNAs) for the CRISPR-Cas9 system have been repurposed to induce sequence-specific repression or activation of gene expression at a genome-wide scale. Different perturbation approaches have different effects and encompass a trade-off between specificity and duration in establishing a measurable perturbation which can result in different biological readouts. However, bench-side strategies are time consuming and expensive. The method described here aims to build a systems-based computational platform to assess pharmacological and biological perturbations at genome-wide network level.Methods: Our network tool NetDecoder (Nucleic Acids Res. 2016; 44(10):e100) that models genome-wide information flow will be used to build context specific protein-protein interaction networks. These networks will be subsequently subjected to in silico perturbations and their impacts on network properties will be assessed. AVANA and Demeter datasets will be used during method validation procedures. Results: Using publicly available expression datasets we generated context specific Breast Cancer networks and individually manipulated nodes and edges of context-specific networks associated with pharmacological FDA approved targets. Our perturbation networks captured cellular rewiring by engulfing new gene players, alterations of the network size and its connectivity. Conclusions: Our in-silico genome wide perturbation platform provides a flexible approach to fine-tune single and tandem manipulations, allowing for inexpensively monitoring a range of pharmacological interventions using large omics data. Citation Format: Cristina Correia, Choong Yong Ung, Cheng Zhang, Scott H. Kaufmann, Hu Li. A genome wide pharmacological perturbation platform [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1226.
Abstract 2248: Environmental factors associated with residual disease after ovarian cancer primary cytoreduction surgery
Phung, Minh Tung , Goode, Ellen L. , Goodman, Marc T. , Richardson, Jean , Grout, Bronwyn, Chase, Anne, Deurloo, Cindy McKinnon, Gorp, Toon Van , Pike, Malcolm C. , Schildkraut, Joellen M. , Pearce, Celeste Leigh , Goodman, Marc T , Phung, Minh Tung , Berchuck, Andrew , Hanley, Gillian E. , Chase, Anne, Karlan, Beth Y. , Matsuo, Keitaro , McLean, Karen, Terry, Kathryn L. , DeFazio, Anna , Webb, Penelope M. , Pharoah, Paul D.P. , Ramus, Susan J.

Mayo Clinic

Cancer Research | June 15, 2022 | Volume: 82 | Issue: 12_Supplement | Pages: 2248-2248

10.1158/1538-7445.am2022-2248 Get It

Abstract Background: Ovarian cancer is the deadliest gynecologic cancer. Standard treatments for advanced stage high-grade serous ovarian cancer, the most common type, include (1) primary cytoreductive surgery (PCS) followed by adjuvant chemotherapy or (2) neoadjuvant chemotherapy (NACT) with interval debulking surgery. Patients in whom PCS is unlikely to yield optimal cytoreduction to no visible residual disease (R0) or who have medical contraindications to PCS are recommended to undergo NACT. Previous studies on associations between environmental factors and risk of any macroscopic residual disease have yielded inconsistent results. We aimed to (1) comprehensively examine the associations between demographic, lifestyle and reproductive factors and risk of residual disease after PCS; and (2) develop and internally validate a risk prediction model based on these factors. Methods: We used pooled data on 3,492 women who had PCS following a diagnosis with advanced stage high-grade serous ovarian, fallopian tube or primary peritoneal cancers from the Ovarian Cancer Association Consortium. Fifteen exposures of interest included age at diagnosis, menopausal status, race/ethnicity, education level, first-degree family history of ovarian cancer, endometriosis, smoking, body mass index, parity, incomplete pregnancy, tubal ligation, use of combined oral contraceptives, depot-medroxyprogesterone acetate, estrogen (ET), and combined estrogen-progestin therapy. We fit logistic regression models to examine each exposure-residual disease association in 80% of the data (n=2,794; random selection of participants). We developed a risk prediction model including the factors with p-values ≤0.2. Area under the receiver operating characteristic curve (AUC) was used to assess the model’s discrimination in the remaining 20% of the data (n=698). Results: Of the 3,492 participants, 2,003 (57%) had residual disease following PCS. Older age at diagnosis was associated with an increased risk of residual disease (OR=1.07 per five years, 95% CI 1.03-1.11). In contrast, a family history of ovarian cancer (OR=0.63, 95% CI 0.42-0.95) or ET use for 5+ years (OR=0.61, 95% CI 0.39-0.96) were associated with achieving R0. These above factors were included in the risk prediction model as were race/ethnicity, personal history of endometriosis, and smoking, whose p-values ≤0.2. The model showed modest performance in the validation set (AUC=0.64). Conclusions: Younger age at diagnosis, family history of ovarian cancer, and long-term ET use were associated with achieving R0 following PCS. Future studies incorporating genetic and clinical factors to improve the risk prediction for residual disease following PCS are warranted. Citation Format: Minh Tung Phung, Andrew Berchuck, Ellen L. Goode, Marc T. Goodman, Gillian E. Hanley, Jean Richardson, Bronwyn Grout, Anne Chase, Cindy McKinnon Deurloo, Beth Y. Karlan, Toon Van Gorp, Keitaro Matsuo, Karen McLean, Malcolm C. Pike, Joellen M. Schildkraut, Kathryn L. Terry, Anna DeFazio, Penelope M. Webb, Paul D. P. Pharoah, Susan J. Ramus, Celeste Leigh Pearce. Environmental factors associated with residual disease after ovarian cancer primary cytoreduction surgery [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2248.
Abstract 2256: Validation of an integrated breast cancer risk model with mammographic density in three prospective cohort studies
Mulder, Charlotta , Jee, Yon Ho , Gao, Chi , Hurson, Amber N. , Vachon, Celine M. , Antoniou, Antonis C. , Choudhury, Parichoy Pal , Yang, Xin , Scott, Christopher G. , Eriksson, Mikael , Hall, Per N , Kraft, Peter , Vachon, Celine M. , Gierach, Gretchen L. , García‐Closas, Montserrat

Mayo Clinic

Cancer Research | June 15, 2022 | Volume: 82 | Issue: 12_Supplement | Pages: 2256-2256

10.1158/1538-7445.am2022-2256 Get It

Abstract Introduction: Incorporation of mammographic density to breast cancer risk models could improve risk stratification to tailor screening and prevention strategies according to risk. However, robust validation of such models in prospective cohort studies is needed to determine their accuracy in identifying women at different risk levels. Methods: We incorporated Breast Imaging and Reporting Data System (BI-RADS) breast density to a literature-based model with questionnaire-based risk factors and a 313-variant polygenic risk score (PRS). The Individualized Coherent Absolute Risk Estimator (iCARE) tool was used to build and validate a 5-year absolute risk model for breast cancer. The model was evaluated for calibration and discrimination in three prospective cohorts of women of European ancestry (1,468 cases, 19,104 controls): US-based Nurses’ Health Study (NHS I and II) and Mayo Mammography Health Study (MMHS); and Sweden-based Karolinska Mammography Project for Risk Prediction of Breast Cancer (KARMA) study. Analyses were done separately for women younger (NHS II, KARMA) and older than 50 years (NHS I, MMHS, KARMA). Improvements in risk stratification were assessed among US non-Hispanic White women aged 50-70 years. Results: For women younger than 50 years, the model with questionnaire-based risk factors, PRS and BI-RADS was well calibrated across risk deciles in NHS II, but overestimated risk at the highest risk decile in KARMA. For women 50 years or older, the model showed good calibration in all studies, with evidence of slight overestimation at the highest risk decile and underestimation at the lowest risk decile. The model with PRS and BI-RADS was well calibrated for women at high-risk in both age groups. Incorporation of BI-RADS to questionnaire-based risk factors and PRS improved risk discrimination: area under the curves (AUC) 67.0% (95% CI: 63.5-70.6%) vs. 65.6% (95% CI: 61.9-69.3%) for models with and without BI-RADS for younger women and 66.1% (95% CI 64.4-67.8%) vs. 65.5% (95% CI: 63.8-67.2%) for older women. The model with BI-RADS identified 18.4% population of non-Hispanic US women 50-70 years old above 3% 5-year risk (used for recommending risk-reducing medication in the US), with 42.4% of future cases expected to occur in this group. Addition of BI-RADS led to the reclassification of ~8.0% of US non-Hispanic White women aged 50-70 years at the high-risk threshold (3% 5-year risk), resulting in identification of 4.2% of additional future cases. Conclusion: Integrating BI-RADS with questionnaire-based risk factors and PRS resulted in improved risk stratification among women of European ancestry, with evidence of slight overestimation of risk for women at elevated risk. Additional validation of the integrated model in diverse populations is needed prior to considering clinical applications. Citation Format: Charlotta V. Mulder, Yon Ho Jee, Xin Yang, Christopher G. Scott, Chi Gao, Amber N. Hurson, Mikael Eriksson, Per Hall, Peter Kraft, Celine M. Vachon, Antonis C. Antoniou, Gretchen Gierach, Montserrat Garcia-Closas, Parichoy Pal Choudhury. Validation of an integrated breast cancer risk model with mammographic density in three prospective cohort studies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2256.
Abstract 494: Role of age, BMI, and tumor subtype in racial/ethnic disparities in breast cancer survival: A pooled analysis of four Alliance adjuvant clinical trials
Lipsyc-Sharf, Marla , Campbell, Jordan D., Muss, Hyman B. , Perez, Edith A. , Ballman, Karla V. , Shulman, Lawrence N. , Carey, Lisa A. , Partridge, Ann H. , Warner, Erica T.

Mayo Clinic

Cancer Research | June 15, 2022 | Volume: 82 | Issue: 12_Supplement | Pages: 494-494

10.1158/1538-7445.am2022-494 Get It

Abstract Background: Previous studies have demonstrated poorer survival of Black women with breast cancer. We assessed whether race/ethnicity was associated with disease-free (DFS) and overall survival (OS) among women with breast cancer enrolled in clinical trials for early-stage breast cancer according to tumor subtype, age, and body mass index (BMI). Methods: 10,011 women enrolled in one of four adjuvant chemotherapy trials: CALGB 9741, CALGB 49907, CALGB 40101, or NCCTG N9831. 9918 participants had available DFS and/or OS data and were included in the analysis. Cox models were used to estimate multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between race/ethnicity and DFS and OS. We compared Non-Hispanic (NH) Black (n=871), Hispanic (n=436), and other race participants (n=283) to NH Whites (n=7889). We assessed associations within strata of age group (<50, 50-<65, or ≥65), tumor subtype (hormone receptor (HR)+/HER2-, HR-/HER2+, or HR-/HER2-), and BMI (<25, 25-<30, or ≥30). Results: In multivariable-adjusted models, NH Black patients under 50 years of age had worse DFS compared to NH White patients (HR: 1.34, 95% CI: 1.10-1.62) and worse OS (HR: 1.64, 95% CI: 1.30-2.07). The differences in DFS and OS persisted in patients ages 50 to <65, though there were no significant differences in DFS or OS between NH Black and NH White patients ages ≥65. Among Hispanic and NH White participants, younger age at diagnosis was associated with greater DFS compared with older age overall while this was not true for NH Black patients. Among patients with HR+/HER2- tumors, NH Black patients when compared to NH White patients had worse DFS (HR 1.33, 95% CI: 1.04-1.70) but there was not a significant difference in OS (HR 1.35, 95% CI: 1.00-1.83). DFS and OS for other tumor subtypes did not significantly differ by race. Among patients with BMI <25, NH Black patients had significantly worse DFS (HR: 1.70, 95% CI: 1.25-2.30) and OS (HR:1.76, 95% CI:1.20-2.58) compared to NH White patients. There was no difference in survival between different race/ethnicity groups among individuals with BMI ≥25. Conclusions: Our results identified subgroups that may contribute to the observed disparities in survival between NH Black and NH White women with early-stage breast cancer. The greatest disparities are among individuals <50 years of age, those with HR+/HER2-, and those with BMI <25. These differences exist even within clinical trial populations with similar initial therapy, suggesting that disparities may be influenced by inequities in survivorship care and long-term treatment, such as endocrine therapy adherence and persistence, and/or differences in tumor or host biology. Support: U10CA180821 and U10CA180882; ClinicalTrials.gov Identifiers: NCT00003088, NCT00005970, NCT00024102, NCT00041119; https://acknowledgments.alliancefound.org Citation Format: Marla Lipsyc-Sharf, Karla V. Ballman, Jordan D. Campbell, Hyman B. Muss, Edith A. Perez, Lawrence N. Shulman, Lisa A. Carey, Ann H. Partridge, Erica T. Warner. Role of age, BMI, and tumor subtype in racial/ethnic disparities in breast cancer survival: A pooled analysis of four Alliance adjuvant clinical trials [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 494.
Abstract 490: De novo individualized disease modules reveal the synthetic penetrance of genes and inform personalized treatment regimens
Weiskittel, Taylor M. , Ung, Choong Yong , Correia, Cristina , Zhang, Cheng , Li, Hu

Mayo Clinic

Cancer Research | June 15, 2022 | Volume: 82 | Issue: 12_Supplement | Pages: 490-490

10.1158/1538-7445.am2022-490 Get It

Abstract Current understandings of individual disease etiology and therapeutics are limited despite great need. To fill the gap, we propose a novel computational pipeline which collects potent disease gene cooperative pathways to envision individualized disease etiology and therapies. Our algorithm constructs individualized disease modules de novo which enable us to elucidate the importance of mutated genes in specific patients and to understand the synthetic penetrance of these genes across patients. We reveal that importance of notorious cancer drivers TP53 and PIK3CA fluctuate widely across breast cancers and peak in tumors with distinct numbers of mutations, and that rarely mutated genes such as XPO1 and PLEKHA1 have high disease module importance in specific individuals. Furthermore, individualized module disruption enables us to devise customized singular and combinatorial target therapies which were highly varied across patients demonstrating the need for precision therapeutics pipelines. As the first analysis of de novo individualized disease modules, we illustrate the power of individualized disease modules for precision medicine by providing deep novel insights on the activity of diseased genes in individuals. Citation Format: Taylor Weiskittel, Cristina Correia, Choong Ung, Cheng Zhang, Hu Li. De novo individualized disease modules reveal the synthetic penetrance of genes and inform personalized treatment regimens [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 490.
Abstract 50: Multi-omics and immune cell profiling of metastatic uveal melanomas
Moser, Justin C. , Shao, Yusra F. , Xiu, Joanne , Sato, Takami , Korn, Michael, Eisenberg, Burton, Gibney, Geoff, Domingo‐Musibay, Evidio , In, Gino, Baca, Yasmine , Dalvin, Lauren A. , Darabi, Sourat , Hoon, Dave S.�B. , Gordon, Michael S.

Mayo Clinic

Cancer Research | June 15, 2022 | Volume: 82 | Issue: 12_Supplement | Pages: 50-50

10.1158/1538-7445.am2022-50 Get It

Abstract Background: Uveal melanoma (UM) is a rare tumor of the eye which is biologically distinct from cutaneous melanoma (CM) and carries a poor prognosis once metastatic. We aimed to examine a multi-omics profile of UM as compared to CM. Methods: A total of 277 UM and 1,297 CM metastatic or primary samples were analyzed using next-generation sequencing (NextSeq, 592 genes and WES, NovaSeq, >700 genes) and whole transcriptome sequencing (WTS; NovaSeq) (Caris Life Sciences). Tumor mutational burden (TMB) was measured by totaling somatic mutations per tumor (TMB-high cutoff >10 mutations per MB). Immune cell fraction was calculated by QuantiSeq. T- cell inflamed score was calculated using gene expression data. Pathway gene enrichment analysis using WTS data was performed using GSEA. Biostatistical significance was determined using chi-square/Fisher-Exact or Wilcoxon rank sum test and adjusted for multiple comparisons. Results: For all cases (primary and metastatic), UM compared to CM had a higher rate of GNAQ/11 (93.8% vs. 2.1% p≤0.001), SF3B1 (20.4% vs 3% p≤0.001), and BAP1 (52.9% vs. 1.5% p≤0.001) mutations. UM also had higher levels of MYC (7% vs 0.9% p≤0.001), NCOA2 (3.1% vs 0.1% p≤0.001), and RUNX1T1 genomic amplifications (2.3% vs 0.2% p≤0.001). Assessing only samples of liver metastases, UM was shown to have higher abundance of M2 macrophages (P≤0.0001) and less abundance of M1 macrophages(P≤0.0001), monocytes(P≤0.0001), CD4 T-cells(P≤0.0001), and regulatory T-cells (p = 0.0003) as compared to CM. GSEA comparison between liver metastases of UM and CM samples showed G2M checkpoint (NES score, 1.60 p≤0.0001) and E2F targets (NES score, 1.58 p=0.002) to be higher in metastatic CM. When comparing T-cell inflamed, intermediate, and non-inflamed tumors from any site, CM or UM, the average Z scores for both G2M and E2F were highest for inflamed and lowest for non-inflamed, P≤0.0001. A similar trend of higher Z score was seen for TMB high vs TMB low tumors, p≤0.0001. Conclusions: UM and CM are characterized by significantly different genomic and transcriptomic alterations, and cellular composition of TME. Further understanding of these characteristics may lead to better treatment strategies for metastatic UM. Citation Format: Justin C. Moser, Yusra F. Shao, Joanne Xiu, Yasmine Baca, Takami Sato, Lauren A. Dalvin, Sourat Darabi, Michael Korn, Burton Eisenberg, Geoff Gibney, Evidio Domingo-Musibay, Gino In, Dave Hoon, Michael S. Gordon. Multi-omics and immune cell profiling of metastatic uveal melanomas [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 50.
Abstract 5012: Deep Gaussian process with uncertainty estimation Improves microsatellite instability prediction based on whole slide image: A retrospective multicenter and multiethnic cohort study
Park, Sunho , Xu, Hongming , Hwang, Tae Hyun , Lee, Sung Hak , Kang, Jeonghyun

Mayo Clinic

Cancer Research | June 15, 2022 | Volume: 82 | Issue: 12_Supplement | Pages: 5012-5012

10.1158/1538-7445.am2022-5012 Get It

Abstract Background: Microsatellite Instability (MSI) is a prognostic and predictive biomarker which can guide treatments including immunotherapy for patients with gastrointestinal cancer. Universal MSI testing would benefit to patients to receive a better therapy, but many patients remain untested. To deliver broadly accessible MSI testing, deep learning models have demonstrated their feasibility for MSI prediction using H&E-stained whole-slide images (WSIs). However, to be deployed into clinical routine care, prediction models should be validated in datasets from multicenter and multiethnic groups. In addition, these models should provide uncertainty of prediction to help clinicians to make informed decisions. Method: We develop a MSI prediction model using WSIs based on Deep Gaussian process (DGP), a Bayesian model being able to model the uncertainty in prediction. We implement a DGP model in the transfer learning, where a WPI is decomposed into multiple non-overlap image patches which are converted to feature vectors by a pretrained convolutional neural network (CNN). Then, the DGP model makes a prediction for an image by averaging score function values at all the feature vectors in the image in weakly supervised learning (WSL). To test our method, we collected H&E stained colorectal/stomach cancer slides (n=1,619) from multi-institutions and multiethnic groups, including TCGA Colorectal (CRC; n=351) and Stomach Adenocarcinoma (STAD; n=174) and six datasets from tertiary hospitals in Korea (i.e., Yonsei-1 (n=174), Yonsei-1-remade (n=146), Yonsei-2 (n=95), St. Mary-1 (n=48), St. Mary-2 (n=50), and Yonsei-CLASSIC trial (n=581)). We also compare our method to multiple deep learning methods, including Densenet, Resnet, Shufflenet, Googlenet, Squeezenet and two WSL models, MIL (Campanell et al., 2019) and CLAM (Lu et al., 2021). Result: In each cancer type, we train each model using TCGA dataset as discovery cohort and tested on the rest of datasets as validation cohort. We use the area under of roc curve (AUC) for the evaluation metric. For the CRC cohorts, our DGP method achieves overall best performance with 0.81 (Yonsei-1), 0.82 (Yonsei-1-remade), 0.89 (Yonsei-2), 0.85 (St. Mary-1) 0.75 (St. Mary-2) AUCs compared to the state-of-the art methods. For the STAD cohorts, our method also achieves overall best performance with 0.74 AUC (Yonsei-classic). In addition, incorporating the uncertainty in prediction measured by our method improves the model’s performance to predict MSI. Specifically, removing cases with prediction results with high uncertainty, which could lead false positive prediction, significantly improves MSI prediction performance. Taken together, these results demonstrate the robustness and generalisability of the DGP model for MSI prediction across multicenter and multiethnic datasets. Citation Format: Sunho Park, Hongming Xu, Sung Hak Lee, Jeonghyun Kang, Tae Hyun Hwang. Deep Gaussian process with uncertainty estimation Improves microsatellite instability prediction based on whole slide image: A retrospective multicenter and multiethnic cohort study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5012.
Abstract 5013: Integrated analysis of intragastric microbiome and human gene expression uncovers genetic, microbial, and immunological associations in gastritis and gastric cancer
Park, Chan Hyuk , Lee, Areum , Hwang, Tae Hyun , Hong, Changjin , Sung, Jaeyun

Mayo Clinic

Cancer Research | June 15, 2022 | Volume: 82 | Issue: 12_Supplement | Pages: 5013-5013

10.1158/1538-7445.am2022-5013 Get It

Abstract Background: Gastric carcinogenesis has been found to be associated with intragastric microbiome, gastric mucosal gene expression, and immune cells comprising the tumor microenvironment separately in independent studies. However, to date, there has been no multi-omic investigations analyzing these biological traits simultaneously. Thus, there is a paucity in our understanding of the intricate relationship between intragastric microbes and the host in gastric disease. To address this gap, we aimed to comprehensively investigate the microbiome, host gene expression, and immune cells in the stomach across a range of different states along the gastric carcinogenesis pathway. Methods: Gastric biopsy samples were obtained from healthy individuals or patients with gastritis or gastric cancer (biopsy cohort, n=30). Surgical samples (of cancer and adjacent severe gastritis tissues) were obtained from gastric cancer patients (surgery cohort, n=40). Using 16S rRNA gene sequencing, RNA-seq, and cell-type enrichment analysis of each participant’s biospecimens, we identified associations between the microbiome and host transcriptome or inferred immune cell types. Results: Microbiome composition and gene expression patterns showed significant differences between disease states (healthy, gastritis, or cancer). Expression of ‘Cell cycle’ pathway genes was enriched in gastric cancer in both biopsy and surgery cohorts. In the biopsy cohort, Helicobacteraceae, which was abundant in gastritis, was highly correlated with FAM3D, which was previously found to be involved in gastrointestinal inflammation. In the surgery cohort, Lachnospiraceae, which was abundant in gastric cancer, was highly correlated with UBD, which is known to regulate mitosis and reduce cell cycle time. Cell-type enrichment analysis revealed lower B cell infiltration in gastric cancer than in gastritis (both cohorts). Tissue-infiltrating B cells were associated with Helicobacteraceae. Conclusions: Associations between the intragastric microbiome, human gene expression, and tissue-infiltrating immune cells are unique to gastric disease state. The findings herein may aid the discovery of novel biomarkers or therapeutic targets of gastric cancer. Citation Format: Chan Hyuk Park, Changjin Hong, A-reum Lee, Jaeyun Sung, Tae Hyun Hwang. Integrated analysis of intragastric microbiome and human gene expression uncovers genetic, microbial, and immunological associations in gastritis and gastric cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5013.
Isotretinoin Laboratory Monitoring in Acne Treatment
Xia, Eric , Han, Jane , Faletsky, Adam , Baldwin, Hilary , Beleznay, Katie, Dréno, Brigitte , Goh, Chee Leok, Gold, Linda Stein , Gollnick, Harald , Herane, María Isabel, Kang, Sewon , Kircik, Leon , Mann, Julianne A. , Nast, Alexander , Oon, Hazel H. , See, Jo Ann, Tollefson, Megha M. , Webster, Guy, Zip, Catherine, Tapper, Elliot B. , Thiboutot, Diane , Zaenglein, Andrea L. , Barbieri, John S. , Bettoli, Vincenzo , See, Jo‐Ann , Tan, Jerry K.L. , Mostaghimi, Arash

Mayo Clinic

JAMA Dermatology | June 15, 2022 | Volume: 158 | Issue: 8 | Pages: 942

10.1001/jamadermatol.2022.2044 | PMID 35704293 Get It

Importance Although isotretinoin may rarely be associated with laboratory abnormalities such as hypertriglyceridemia, the optimal approach to laboratory monitoring is uncertain, and there is wide variation in clinical practice. Objective To establish a consensus for isotretinoin laboratory monitoring among a diverse, international cohort of clinical and research experts in acne. Design, Setting, and Participants Using a modified electronic Delphi process, 4 rounds of anonymous electronic surveys were administered from 2021 to 2022. For laboratory tests reaching consensus (≥70% agreement) for inclusion, questions regarding more time-specific monitoring throughout isotretinoin therapy were asked in subsequent rounds. The participants were international board-certified dermatologist acne experts who were selected on a voluntary basis based on involvement in acne-related professional organizations and research. Main Outcomes and Measures The primary outcome measured was whether participants could reach consensus on key isotretinoin laboratory monitoring parameters. Results The 22 participants from 5 continents had a mean (SD) time in practice of 23.7 (11.6) years and represented a variety of practice settings. Throughout the 4-round study, participation rates ranged from 90% to 100%. Consensus was achieved for the following: check alanine aminotransferase within a month prior to initiation (89.5%) and at peak dose (89.5%) but not monthly (76.2%) or after treatment completion (73.7%); check triglycerides within a month prior to initiation (89.5%) and at peak dose (78.9%) but not monthly (84.2%) or after treatment completion (73.7%); do not check complete blood cell count or basic metabolic panel parameters at any point during isotretinoin treatment (all >70%); do not check gamma-glutamyl transferase (78.9%), bilirubin (81.0%), albumin (72.7%), total protein (72.7%), low-density lipoprotein (73.7%), high-density lipoprotein (73.7%), or C-reactive protein (77.3%). Conclusions and Relevance This Delphi study identified a core set of laboratory tests that should be evaluated prior to and during treatment with isotretinoin. These results provide valuable data to guide clinical practice and clinical guideline development to optimize laboratory monitoring in patients treated with isotretinoin.
Abstract 5024: Aging patterns in five disparate cancer entities indicate a novel senescent cell population with therapeutic targetability
Saul, Dominik , Kosinsky, Robyn Laura

Mayo Clinic

Cancer Research | June 15, 2022 | Volume: 82 | Issue: 12_Supplement | Pages: 5024-5024

10.1158/1538-7445.am2022-5024 Get It

Abstract Human aging is associated with molecular changes and cellular degeneration, resulting in a significant increase in cancer incidence with age. Whether aging as its own entity can be initiator of putative cancerous developments, the transcriptional changes underlying the cancerous development itself are largely unknown. Here, we analyzed publicly available bulk RNA sequencing data of 328 control vs. 453 cancer samples in combination with single cell sequencing datasets from 49 control vs. 105 cancer patients. Using widely accepted aging-associated gene sets, we assembled key features of aging and their reflection in cancer development in five distinct cancer entities with an age-dependent increase of incidence, i.e. chronic myeloid leukemia (CML), colorectal cancer (CRC), hepatocellular carcinoma (HCC), lung cancer (LC) and pancreatic ductal adenocarcinoma (PDAC). After confirmation of the aging/senescence-induced gene (ASIG) expression to be upregulated in malignant diseases compared to healthy controls, we elucidated the importance of ASIGs during single cell development, making use of pseudotime analyses. In each entity, distinct temporally late enrichment states were carved out, and their transcriptional connectivity next to epigenetic control verified. Remarkably, we were able to demonstrate that all cancer entities analyzed in this study comprised cell populations expressing ASIGs. Except for pancreatic cancer, all entities accounted for subpopulations with aging associated patterns. Using a novel pipeline to repurpose FDA-approved drugs and combinations on a single cell level, we discovered a path for novel treatment regimen on a tumor-specific basis. These respective cellular subpopulations demonstrate pillars of susceptibility within the complex tumor microenvironment and serve as a basis for future studies on the role of aging and senescence in human malignancies. Citation Format: Dominik Saul, Robyn Laura Kosinsky. Aging patterns in five disparate cancer entities indicate a novel senescent cell population with therapeutic targetability [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5024.